Dr. Reddy’s Generic Semaglutide Receives Green Signal from Canada

Dr. Reddy’s Laboratories is set to launch its generic Semaglutide injection in the Canadian market soon. The company announced that the drug has received approval from Health Canada, marking the first time the regulator has approved a generic version of semaglutide. The medication, used for managing Type 2 Diabetes, was recently introduced in India under the brand name “Obeda.”

The company described the approval as a significant milestone in its journey, highlighting its expertise in developing complex generic medicines. CEO Erez Israeli stated that this development reflects the firm’s strong capabilities in advanced drug manufacturing. He added that the approval will enable patients in Canada to access semaglutide at more affordable prices. The drug will be launched in the Canadian market in 2 mg and 4 mg pen formats.